Press Release: Execution of a share buyback agreement for up to €2 billion
07 Fevereiro 2025 - 3:00AM
UK Regulatory
Press Release: Execution of a share buyback agreement for up to €2
billion
Execution of a share buyback agreement for
up to €2 billion
Paris, February 7, 2025. On
January 30, 2025, Sanofi announced its intention to execute a share
buyback program in 2025 of €5 billion, preferably through block
trades and in the open market with the purpose of cancellation.
A first tranche of this program was announced on
February 3, 2025, and executed on February 5, 2025, for an amount
of €3 billion, through an off-market block trade with the
long-standing shareholder L’Oréal.
On February 6, 2025, Sanofi has entered into a
mandate with an investment service provider for the second tranche
of this program. Under the terms of this mandate, Sanofi will
repurchase its own shares for a total consideration of up to €2
billion, between February 7, 2025 and December 31, 2025 at the
latest1.
About Sanofi
We are an innovative global healthcare company, driven by one
purpose: we chase the miracles of science to improve people’s
lives. Our team, across the world, is dedicated to transforming the
practice of medicine by working to turn the impossible into the
possible. We provide potentially life-changing treatment options
and life-saving vaccine protection to millions of people globally,
while putting sustainability and social responsibility at the
center of our ambitions. Sanofi is listed on EURONEXT: SAN and
NASDAQ: SNY
Media Relations
Sandrine Guendoul | + 33 6 25 09 14 25 |
sandrine.guendoul@sanofi.com
Evan Berland | + 1 215 432 0234 |
evan.berland@sanofi.com
Léo Le Bourhis | + 33 6 75 06 43 81
| leo.lebourhis@sanofi.com
Nicolas Obrist | + 33 6 77 21 27 55
| nicolas.obrist@sanofi.com
Victor Rouault | + 33 6 70 93 71 40
| victor.rouault@sanofi.com
Timothy Gilbert | + 1 516 521 2929 |
timothy.gilbert@sanofi.com
Investor Relations
Thomas Kudsk Larsen |+ 44 7545 513 693 |
thomas.larsen@sanofi.com
Alizé Kaisserian | + 33 6 47 04 12 11 |
alize.kaisserian@sanofi.com
Felix Lauscher | + 1 908 612
7239 | felix.lauscher@sanofi.com
Keita Browne | + 1 781 249 1766 |
keita.browne@sanofi.com
Nathalie Pham | + 33 7 85 93 30 17 |
nathalie.pham@sanofi.com
Tarik Elgoutni | + 1 617 710 3587 |
tarik.elgoutni@sanofi.com
Thibaud Châtelet | + 33 6 80 80 89 90
| thibaud.chatelet@sanofi.com
Sanofi forward-looking
statements
This press release contains forward-looking statements as defined
in the Private Securities Litigation Reform Act of 1995, as
amended. Forward-looking statements are statements that are not
historical facts. These statements include projections and
estimates regarding the marketing and other potential of the
product, or regarding potential future revenues from the product.
Forward-looking statements are generally identified by the words
“expects”, “anticipates”, “believes”, “intends”, “estimates”,
“plans” and similar expressions. Although Sanofi’s management
believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various
risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi, that could cause actual
results and developments to differ materially from those expressed
in, or implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other
things, unexpected regulatory actions or delays, or government
regulation generally, that could affect the availability or
commercial potential of the product, the fact that product may not
be commercially successful, the uncertainties inherent in research
and development, including future clinical data and analysis of
existing clinical data relating to the product, including post
marketing, unexpected safety, quality or manufacturing issues,
competition in general, risks associated with intellectual property
and any related future litigation and the ultimate outcome of such
litigation, and volatile economic and market conditions, and the
impact that pandemics or other global crises may have on us, our
customers, suppliers, vendors, and other business partners, and the
financial condition of any one of them, as well as on our employees
and on the global economy as a whole. The risks and uncertainties
also include the uncertainties discussed or identified in the
public filings with the SEC and the AMF made by Sanofi, including
those listed under “Risk Factors” and “Cautionary Statement
Regarding Forward-Looking Statements” in Sanofi’s annual report on
Form 20-F for the year ended December 31, 2023. Other than as
required by applicable law, Sanofi does not undertake any
obligation to update or revise any forward-looking information or
statements.
1 Subject to the renewal, as the case may be, of
the buyback and cancellation resolutions by the 2025 shareholders
meeting.
Sanofi (EU:SAN)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025
Sanofi (EU:SAN)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025
